Form 8-K - Current report:
SEC Accession No. 0001420720-25-000020
Filing Date
2025-04-22
Accepted
2025-04-22 16:41:30
Documents
17
Period of Report
2025-04-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20250421x8k.htm   iXBRL 8-K 38796
2 EX-10.1 ibio-20250421xex10d1.htm EX-10.1 244584
3 EX-99.1 ibio-20250421xex99d1.htm EX-99.1 18003
4 GRAPHIC ibio-20250421xex99d1001.jpg GRAPHIC 3317
  Complete submission text file 0001420720-25-000020.txt   486748

Data Files

Seq Description Document Type Size
5 EX-101.SCH ibio-20250421.xsd EX-101.SCH 4268
6 EX-101.DEF ibio-20250421_def.xml EX-101.DEF 3991
7 EX-101.LAB ibio-20250421_lab.xml EX-101.LAB 13976
8 EX-101.PRE ibio-20250421_pre.xml EX-101.PRE 10319
19 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20250421x8k_htm.xml XML 4617
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 25858228
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)